OneSource Specialty Pharma Clarifies Operations Amid Partner Supply Delay of Semaglutide
OneSource Specialty Pharma Ltd has addressed clarifications regarding the reported delay in commercial supplies of Semaglutide by Dr. Reddy's Laboratories (DRL), reaffirming that the disruption does not materially impact its operational status.The company noted that while it maintains a long-standing partnership with DRL as a Manufacturing Partner for Generic Semaglutide Injection, the delay in commercial supplies disclosed by DRL has no material financial or operational bearing on OneSource Specialty Pharma Ltd.
Despite the situation involving the partner's supply chain, OneSource confirmed strong market demand and commitment to its operations. The company stated that it has ample demand for the product from other customers, including commitments originating from Canada, and all current capacities are fully committed.
Looking ahead, OneSource is actively executing expansion plans. Significant new capacities are being added starting in the current quarter and planned later in the year. These expansions are intended to ensure the company can supply all of DRL's demand once their production is ready.
OneSource remains focused on carrying out its growth strategies and serving both global customers and its domestic market with high standards of reliability and quality supply continuity.
ONESOURCE Stock Price Movement
As of 10:53 AM, Onesource Specialty Pharma Limited shares are edging higher to ₹1655.40, buoyed by a solid 2.69% surge in live trading. The stock is seeing active movement across the market, currently trading on a volume of 114,829 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.